These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


970 related items for PubMed ID: 19843632

  • 1. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B.
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [Abstract] [Full Text] [Related]

  • 2. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

  • 3. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y, Zhang B.
    Mol Cancer Res; 2008 Dec 01; 6(12):1861-71. PubMed ID: 19074831
    [Abstract] [Full Text] [Related]

  • 4. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC.
    Cancer Res; 2005 Jun 01; 65(11):4799-808. PubMed ID: 15930300
    [Abstract] [Full Text] [Related]

  • 5. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
    Choi SY, Kim MJ, Chung HY, Lee SJ, Jang YJ.
    Oncol Rep; 2007 Jan 01; 17(1):175-84. PubMed ID: 17143496
    [Abstract] [Full Text] [Related]

  • 6. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR.
    Biochem Pharmacol; 2006 Jul 28; 72(3):293-307. PubMed ID: 16753135
    [Abstract] [Full Text] [Related]

  • 7. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N, Poulaki V, Mitsiades C, Tsokos M.
    Cancer Res; 2001 Mar 15; 61(6):2704-12. PubMed ID: 11289151
    [Abstract] [Full Text] [Related]

  • 8. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

  • 9. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M, Ettenberg SA, Nau MM, Lipkowitz S.
    Gynecol Oncol; 2001 Jun 15; 81(3):380-90. PubMed ID: 11371126
    [Abstract] [Full Text] [Related]

  • 10. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J, Bu J, Hao Y, Chen F.
    Prostate Cancer Prostatic Dis; 2005 Jun 15; 8(3):274-9. PubMed ID: 15897917
    [Abstract] [Full Text] [Related]

  • 11. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH, de Vries EG, Meersma GJ, Hougardy BM, van der Zee AG, de Jong S.
    Int J Radiat Oncol Biol Phys; 2008 Oct 01; 72(2):543-52. PubMed ID: 18793956
    [Abstract] [Full Text] [Related]

  • 12. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
    Chen X, Kandasamy K, Srivastava RK.
    Cancer Res; 2003 Mar 01; 63(5):1059-66. PubMed ID: 12615723
    [Abstract] [Full Text] [Related]

  • 13. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA.
    Cancer Res; 2006 Jun 01; 66(11):5867-74. PubMed ID: 16740726
    [Abstract] [Full Text] [Related]

  • 14. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Tomek S, Horak P, Pribill I, Haller G, Rössler M, Zielinski CC, Pils D, Krainer M.
    Gynecol Oncol; 2004 Jul 01; 94(1):107-14. PubMed ID: 15262127
    [Abstract] [Full Text] [Related]

  • 15. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 16. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

  • 17. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
    Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH.
    Biochem Pharmacol; 2009 Apr 15; 77(8):1328-36. PubMed ID: 19426671
    [Abstract] [Full Text] [Related]

  • 18. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B.
    Clin Cancer Res; 2001 Dec 15; 7(12):3874-83. PubMed ID: 11751478
    [Abstract] [Full Text] [Related]

  • 19. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T.
    Cancer Res; 2005 Jul 15; 65(14):6364-70. PubMed ID: 16024639
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 49.